Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells

Journal of Immunology

Volumn 161, Issue 12, 1998, Pages 6552-6558

  La Motte, Ross N ^a   Sharpe, Arlene H ^b   Bluestone, Jeffrey A ^c   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE DISRUPTION; GENETIC TRANSFECTION; HOST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; MAST-CELL SARCOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0032534599     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Janeway, C. A. J., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76:275.
2. Jenkins, M. K., and J. G. Johnson. 1993. Molecules involved in T-cell costimulation. Curr. Opin. Immunol. 5:361.
3. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
4. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
5. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
6. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
7. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnight, J. Kim, L. Du, D. B. Lombard, G. S. Gray, L. M. Nadler, and A. H. Sharpe. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
8. Larsen, C. P., S. C. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. Hodes, R. P. Lowry, and T. C. Pearson. 1994. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152:5208.
9. Chang, C. H., M. Furue, and K. Tamaki. 1995. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-γ or by interleukin-10. Eur. J. Immunol. 25:394.
10. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J .Exp. Med. 180:631.
11. Noelle, R. J. 1996. CD40 and its ligand in host defense. Immunity 4:415.
12. Lenschow, D. J., A. I. Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153:1990.
13. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
14. + T cells by B7-transfected melanoma cells. Science 259:368.
15. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellström, and K. E. Hellström. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
16. Yang, G., K. E. Hellström, I. Hellström, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
17. La Motte R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
18. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
19. Matulonis, U., C. Dosiou, G. Freeman, C. Lamont, P. Mauch, L. M. Nadler, and J. D. Griffin. 1996. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156:1126.
20. Allison, J. P., A. A. Hurwitz, and D. R. Leach. 1995. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol. 7:682.
21. Yang, G., K. E. Hellström, M. T. Mizuno, and L. Chen. 1995. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol. 155:3897.
22. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
23. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
24. Sharpe, A. H. 1995. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr. Opin. Immunol. 7:389.
25. Razi-Wolf, Z., G. J. Freeman, F. Galvin, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89:4210.
26. Baskar, S., V. K. Clements, L. H. Glimcher, N. Nabavi, and S. Ostrand-Rosenberg. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156:3821.
27. Albert, M. L., B, Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
28. Yang, G., M. T. Mizuno, K. E. Hellström, and L. Chen. 1997. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol. 158:851.
29. Rosato, A., A. Zambon, B. Macino, S. Mandruzzato, V. Bronte, G. Milan, P. Zanovello, and D. Collavo. 1996. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. Int. J. Cancer 65:847.
30. Chang, C.-H., M. Furue, and K. Tamaki. (1995). B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and down-regulated by interferon-γ or by interleukin-10. Eur. J. Immunol. 25:394.
31. Roy, M., A. Aruffo, J. Ledbetter, P. Linsley, M. Kehry, and R. Noelle. 1995. Studies on the interdependency of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:596.
32. Azuma, M., M. Cayabyab, D. Buck, J. H. Phillips, and L. L. Lanier. 1992. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J. Immunol. 149:1115.
33. Nishio, M., J. Spielman, R. K. Lee, D. L. Nelson, and E. R. Podack. 1996. CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis. J. Immunol. 157:4347.